Evidence map›Paper›PMID 39814561›Full record

ArticleBriefings in bioinformatics2024

Explainable deep neural networks for predicting sample phenotypes from single-cell transcriptomics.

Jordi Martorell-Marugán, Raúl López-Domínguez, Juan Antonio Villatoro-García, Daniel Toro-Domínguez, Marco Chierici, Giuseppe Jurman, Pedro Carmona-Sáez

Abstract read
In one paragraph

Article in Briefings in bioinformatics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Jordi Martorell-MarugánGENYO, Centre for Genomics and Oncological Research: Pfizer / University of Granada / Andalusian Regional Government, PTS Granada, Avenida de la Ilustración 114, Granada 18016, Spain.ORCID 0000-0002-5186-0735
Raúl López-DomínguezGENYO, Centre for Genomics and Oncological Research: Pfizer / University of Granada / Andalusian Regional Government, PTS Granada, Avenida de la Ilustración 114, Granada 18016, Spain.ORCID 0000-0001-8634-117X
Juan Antonio Villatoro-GarcíaGENYO, Centre for Genomics and Oncological Research: Pfizer / University of Granada / Andalusian Regional Government, PTS Granada, Avenida de la Ilustración 114, Granada 18016, Spain.ORCID 0000-0001-5752-7784
Daniel Toro-DomínguezUnit of Inflammatory Diseases, Department of Environmental Medicine, Karolinska Institutet, Nobels väg 13, Solna 171 77, Sweden.ORCID 0000-0001-8440-312X
Marco ChiericiData Science for Health Research Unit, Fondazione Bruno Kessler, Via Sommarive 18, Trento 38123, Italy.ORCID 0000-0001-9791-9301
Giuseppe JurmanData Science for Health Research Unit, Fondazione Bruno Kessler, Via Sommarive 18, Trento 38123, Italy.ORCID 0000-0002-2705-5728
Pedro Carmona-SáezGENYO, Centre for Genomics and Oncological Research: Pfizer / University of Granada / Andalusian Regional Government, PTS Granada, Avenida de la Ilustración 114, Granada 18016, Spain.ORCID 0000-0002-6173-7255

Funding

FEDER/Junta de Andalucía-Consejería de Universidad, Investigación e Innovación PID2020-119032RB-I00Universidad de Granada PP2024.PP-07
6 · The paper itself

Abstract

Recent advances in single-cell RNA-Sequencing (scRNA-Seq) technologies have revolutionized our ability to gather molecular insights into different phenotypes at the level of individual cells. The analysis of the resulting data poses significant challenges, and proper statistical methods are required to analyze and extract information from scRNA-Seq datasets. Sample classification based on gene expression data has proven effective and valuable for precision medicine applications. However, standard classification schemas are often not suitable for scRNA-Seq due to their unique characteristics, and new algorithms are required to effectively analyze and classify samples at the single-cell level. Furthermore, existing methods for this purpose have limitations in their usability. Those reasons motivated us to develop singleDeep, an end-to-end pipeline that streamlines the analysis of scRNA-Seq data training deep neural networks, enabling robust prediction and characterization of sample phenotypes. We used singleDeep to make predictions on scRNA-Seq datasets from different conditions, including systemic lupus erythematosus, Alzheimer's disease and coronavirus disease 2019. Our results demonstrate strong diagnostic performance, validated both internally and externally. Moreover, singleDeep outperformed traditional machine learning methods and alternative single-cell approaches. In addition to prediction accuracy, singleDeep provides valuable insights into cell types and gene importance estimation for phenotypic characterization. This functionality provided additional and valuable information in our use cases. For instance, we corroborated that some interferon signature genes are consistently relevant for autoimmunity across all immune cell types in lupus. On the other hand, we discovered that genes linked to dementia have relevant roles in specific brain cell populations, such as APOE in astrocytes.

Indexed as

Deep LearningGene Expression ProfilingNeural Networks, ComputerSingle-Cell AnalysisTranscriptomeAlgorithmsAlzheimer DiseaseCOVID-19HumansLupus Erythematosus, SystemicPhenotypeSARS-CoV-2Sequence Analysis, RNAAlzheimer’s diseaseartificial intelligencecomplex diseasesdeep learningsingle-cell RNA-Sequencingsystemic lupus erythematosus

Identifiers

PMID39814561
PMCPMC11735047

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.